末梢神經病變治療的市場規模、佔有率、展望、機會 (2022年～2030年):各適應症、治療 (藥物治療、非藥物治療)、終端用戶、地區

主要進入經營者著重在產品的上市和核准等的成長策略採用，這促進在預測期間內的全球末梢神經病變治療市場成長。

本報告提供全球末梢神經病變治療的市場調查，市場定義和概要，市場成長的各種影響因素分析，法律規章、償付環境，開發平台的分析，市場規模的變化、預測，各種區分、各地區/主要國家的明細，競爭環境，主要企業簡介等彙整資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

第3章 市場動態、法規、趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機會
• 影響分析
• 開發平台分析
• 償付情境
• 流行病學
• PEST分析
• 法規情境
• 新產品的認證、銷售
• 收購、聯盟
• 市場趨勢

第4章 全球末梢神經病變治療市場:COVID-19影響

• COVID-19對醫療保健部門全體的影響
• COVID-19:流行病學
• COVID-19臨床試驗和醫藥品開發的影響

第5章 全球末梢神經病變治療市場:各適應症

• 糖尿病性末梢神經病變
• 化療誘發性末梢神經病變
• 特發性末梢神經病變
• 其他

第6章 全球末梢神經病變治療市場:各治療

• 藥物治療

第7章 全球末梢神經病變治療市場:各終端用戶

• 醫院
• 門診中心
• 其他

第8章 全球末梢神經病變治療市場:各地區

• 北美
• 南美
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章 競爭情形

• 熱圖分析
  • Abbott Laboratories
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Johnson &Johnson
  • Reddy's Laboratories Ltd
  • Pfizer, Inc.
  • Cipla Inc.
  • Lupin Limited
  • Averitas Pharma, Inc.
  • NeuroBo Pharmaceuticals, Inc
• 分析師的見解

第10章 Section

Peripheral neuropathy is a disorder of the peripheral nerves. These nerves send messages between the central nervous system, the brain and the spinal cord, and the rest of the body. Peripheral neuropathy can result from traumatic injuries, infections, metabolic problems, inherited causes, and exposure to toxins. One of the most common causes is diabetes. Peripheral neuropathy caused by either type 1 diabetes or type 2 diabetes is called diabetic polyneuropathy. Individual with peripheral neuropathy generally describe the pain as stabbing, burning or tingling. In many cases, symptoms improve, especially if caused by a treatable condition. Medications such as Lyrica, Cymbalta, etc can reduce the pain of peripheral neuropathy.

Market Dynamics

Key players operating in the global peripheral neuropathy treatment market are focusing on adoption growth strategies such as product launch, and approval which are expected to drive the market growth during the forecast period. For instance, in July 2019, Alembic Pharmaceuticals Limited, an Indian pharmaceutical company, announced that it received the approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Pregabalin Capsules that is used for peripheral neuropathic pain. Moreover, various government agencies focusing on investing funds in academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy which is expected to drive the market growth over forecast period. For instance, in November 2018, the U.S. National Cancer Institute awarded/invested US$ 2.3 Mn in Indiana University School of Medicine, a research institute in the U.S. The investment was made in Indiana University School of Medicine to accelerate the research and development of small, targeted molecule called APX3330 to prevent or reverse chemotherapy induced peripheral neuropathy (CIPN) caused by cancer drugs.

Key features of the study:

• This report provides an in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global peripheral neuropathy treatment market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy's Laboratories Ltd, Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., and NeuroBo Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market.

Detailed Segmentation:

• Global Peripheral Neuropathy Treatment Market, By Indication :
• Diabetic Peripheral Neuropathy
• Chemotherapy-induced Peripheral Neuropathy
• Idiopathic Peripheral Neuropathy
• Others
• Global Peripheral Neuropathy Treatment Market, By Treatment :
• Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
• Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
• Global Peripheral Neuropathy Treatment Market, By End User :
• Hospital
• Ambulatory Centers
• Others
• Global Peripheral Neuropathy Treatment Market, By Region:

• North America
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange

o

• Others
• By End User
• Hospital
• Ambulatory Centers
• Others
• By Country
• U.S.
• Canada
• Latin America
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others

o

• By End User
• Hospital
• Ambulatory Centers
• Other
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
• Abbott Laboratories*
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Johnson & Johnson
• Dr. Reddy's Laboratories Ltd
• Pfizer, Inc.
• Cipla Inc.
• Lupin Limited
• Averitas Pharma, Inc.
• NeuroBo Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Indication
  • Market Snapshot, By Treatment
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunity
• Impact Analysis
• Pipeline Analysis
• Reimbursement Scenario
• Epidemiology
• PEST Analysis
• Regulatory Scenario
• New Product Approvals/Launches
• Acquisition and Collaboration
• Market Trends

4. Global Peripheral Neuropathy Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

• COVID-19 Impact on Overall Healthcare Sector
• COVID-19 Epidemiology
• COVID-19 Impact on Clinical Trials and Drug Development

5. Global Peripheral Neuropathy Treatment Market, By Indication, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Diabetic Peripheral Neuropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Chemotherapy-induced Peripheral Neuropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Idiopathic Peripheral Neuropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Peripheral Neuropathy Treatment Market, By Treatment, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Pharmacological Therapies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others

7. Global Peripheral Neuropathy Treatment Market, By End User, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Hospital
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Ambulatory Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

8. Global Peripheral Neuropathy Treatment Market, By Region, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2028
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • U.S.
  • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

• Heat Map Analysis
  • Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Reddy's Laboratories Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Cipla Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Lupin Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Averitas Pharma, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • NeuroBo Pharmaceuticals, Inc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us